Skip to main content

Table 2 Comparisons of clinical parameters of SLE patients with and without amenorrhea

From: Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study

  With amenorrhea Without amenorrhea p OR (95% CI)
  n = 26 n = 36   
Age (years) 33 (18-45) 30 (19-44) 0.20 1.0 (1.0-1.1)
   Subjects < 40 years old 17 (65%) 34 (94%) 0.005 9.0 (1.7-46.4)
   Subjects ≥ 40 years old 9 (35%) 2 (6%)   
Duration of SLE (months) 5 (1-241) 3 (1-128) 0.77 1.0 (1.0-1.0)
SLE manifestation     
   Nephritis 12 (46%) 16 (44%) 1.00 1.1 (0.4-3.0)
   CNS lupus 5 (19%) 3 (8%) 0.26 2.6 (0.6-12.1)
   Vasculitis 2 (8%) 4 (11%) 1.00 0.7 (0.1-3.9)
   Cytopenia 8 (31%) 9 (25%) 0.77 1.3 (0.4-4.1)
Positive anti-SS-A/Ro antibodies 14 (54%) 21 (58%) 0.80 0.8 (0.3-2.3)
Positive anti-U1-RNP antibodies 10 (38%) 16 (44%) 0.61 0.7 (0.3-1.9)
SLEDAI-2K 13.5 (5-31) 11.5 (2-26) 0.35 0.9 (0.9-1.0)
Max. dose of prednisolone (mg) 50 (25-125) 45 (14-100) 0.43 1.0 (1.0-1.0)
Glucocorticoid pulse therapy 6 (23%) 6 (17%) 0.54 1.5 (0.4-5.3)
IVCY 17 (65%) 12 (33%) 0.02 3.8 (1.3-11.0)
Total dose of cyclophosphamide (mg) 1300 (500-6500) 1000 (500-2700) 0.69 -
Total number of IVCY (time) 2 (1-13) 2.5 (1-5) 1.00 -
  1. *Except where indicated otherwise, values of continuous data are the median (range). Total dose of IVCY and total number of IVCY were calculated with the subjects in the IVCY group only.
  2. p values were determined by Fisher's exact test or Mann-Whitney U test.
  3. ORs of numerical valuables were determined by univariate logistic regression.
  4. IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, OR odds ratio, CI confidence interval, CNS central nervous system, SLEDAI-2K systemic lupus erythematosus disease activity index 2000.